This webinar is brought to you by
(Agenda in US PST time zone)
08:00 – 08:10
08:15 – 08:35
Beauty and the Beast in MEMS-based Healthcare Startups
Presented by: Anil Achyuta, Investment Director – TDK Ventures
View Full Details
08:40 – 09:00
Utilizing MEMS Technology to Automate Ex-Vivo Delivery of Molecules into Cells
Presented by: Dr. Anil Narasimha, CEO – Mekonos
View Full Details
09:05 – 09:25
Topic MEMS Fabless Startup Support in Asia
Presented by: Dr. Douglas Sparks, CTO – Hanking Electronics Ltd
View Full Details
09:30 – 09:35
This webinar has now passed. View our latest events and webinars below:
Investment Director – TDK Ventures
Anil Achyuta is an investment director and founding member of TDK Ventures ($200M AUM) that invests globally in early-stage startups that leverage fundamental material science to unlock an attractive and sustainable future for the world. It is a wholly owned subsidiary of TDK Corporation, a world leader in electronic solutions for the smart-products universe. Anil is passionate about the energy and healthcare sectors, as he believes these are the most impactful areas in building a sustainable future, a mission that is directly in line with TDK Ventures’ goals.
At TDK Ventures, he has reviewed over 1500 start-ups and invested in nine companies:
1) Autoflight – an electric vertical take-off and landing company;
2) Genetesis – a magnetic imaging-based cardiac diagnostics company (Board Member);
3) Origin – a 3-D printing mass-manufacturing company;
4) Exo – a hand-held 3-D ultrasound imaging company;
5) GenCell – an ammonia-to-energy hydrogen fuel-cell company;
6) Mojo Vision – an augmented-reality contact-lens company,
7) Battery Resourcers – a direct-to-cathode lithium ion battery recycling company (Board Observer), and
8) Fabric8 Labs – an electrochemical deposition metal 3D printing company (Board Observer),
9) AM Batteries – a dry-electrode-based lithium ion battery manufacturing company.
Of his nine investments, Anil has secured two exits: GenCell IPO’d on the Tel Aviv Stock Exchange (GNCL:IT), and Origin, which was acquired by the #1 3-D printing company in the world, Stratasys, for $100M.
Anil was voted one of the Rising Stars in 2021 by Venture Capital Journal and was ranked #2 Rising Star in 2021 out of 20,000 corporate venture managers globally.
Prior to TDK Ventures, Anil held leadership roles at Fortune 500 companies including L’Oréal, Johnson & Johnson, GlaxoSmithKline, and Draper. He has a Ph.D. in Chemical Engineering from Northeastern University and received his MBA from the University of Florida – Warrington College of Business. He has authored over 15 peer-reviewed journal publications and holds five U.S. patents.
Abstract coming soon…
TDK Ventures Inc. invests in startups to bolster innovation in materials science, energy/power and related areas typically underrepresented in venture capital portfolios. Established in 2019 as a wholly-owned subsidiary of TDK Corporation, the corporate venture company’s vision is to propel the digital and energy transformations of segments such as health and wellness, next-generation transportation, robotics and industrial, mixed reality and the wider IoT/IIoT markets. TDK Ventures will co-invest and support promising portfolio companies by providing technical expertise and access to global markets where TDK operates. Interested startups or investment partners may contact TDK Ventures: www.tdk-ventures.com or .
CEO – Mekonos
Dr. Anil Narasimha is an accomplished scientist and founder in the field of personalized medicine. He co-founded Mekonos in 2017 to come up with a platform to automate delivery of payloads into fragile cell types while remaining precise and scalable. Prior to Mekonos, Anil completed his PhD at UC San Diego before moving to Stanford University to become a postdoctoral fellow in Dr. Michael Snyder’s laboratory. There, he was introduced to cell and gene therapy and identified some of the pitfalls associated with it, including the lack of automation and precision when it came to delivering payloads into primary cells. His goal is to utilize his platform to make cell and gene therapies more accessible.
Delivery of molecules into fragile cell types is currently very challenging, especially for applications such as cell and gene therapy. Challenges include a lack of precision and automation that contribute to these therapies being at a very high price point and inaccessible to the mainstream population. At Mekonos, we are developing a platform taking advantage of MEMS technology to add a layer of automation and precision to the drug development pipeline. Through actuated nanoneedles, we inject single cells with a specific payload at high efficiency and cell viability. We aim to create a platform that can be a solution for both R&D as well as manufacturing of these breakthrough therapies.
Company profile coming soon…
CTO – Hanking Electronics Ltd
Dr. Douglas Sparks is the CTO of Hanking Electronics which built the first 200mm pure MEMS fab in China. He has lead technology acquisition, process and MEMS related product development at Hanking Electronics. He is the Vice President of the Asia-Pacific region for MANCEF, the Micro-Nano Commercialization Education Foundation. Doug also founded a microsensor packaging company called NanoGetters, was the EVP at Integrated Sensing Systems where he launched nine microfluidic sensor products. Doug worked in automotive sensors and semiconductor fabs with Delphi. He holds a PhD in materials engineering from Purdue University has published more than 150 technical papers and has 70 issued patents.
Fabless technology startups require infrastructure to successfully launch complex products. This talk will cover the supporting institutes, organizations and foundries in Asia that are being used by regional MEMS startups. MEMS and product design and development strategies will be discussed. MEMS and CMOS fabs, OSATS in Asia for the different stages of company growth will be reviewed from concept to high volume manufacturing.
Company profile coming soon
View more of our events below